Acadia Pharmaceuticals Inc. (ACAD)

Acadia Pharmaceuticals Inc. (ACAD) is a healthcare company (biotechnology) based in the United States. The share price is $18.20, down 2.52% on the day, which values the company at $3.15B. Price as of 17 Nov 2026, 17:30 UTC, from Yahoo Finance.

Key facts

Share price
$18.20−2.52% today
Market value
$3.15B
P/E ratio
8.6×last 12 months
Forward P/E
16.8×
Funk Score
75/100
Against its own history
Well below its usual priceusual price $28.25
200-week average
$21.5516% below
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Acadia Pharmaceuticals Inc. in more detail

ACAD trades at 8.6× its last twelve months' earnings, 16.8× next year's expected earnings, 2.6× sales. Measured against its own history, the price is 36% below what its usual multiples would imply ($28.25) — well below its usual price. It sits 16% below its 200-week average of $21.55.

Over the last five fiscal years Acadia Pharmaceuticals Inc. has compounded revenue 19.4% a year. Its Funk Score is 75 out of 100 (financial strength 9.2, profitability 5.8, growth 9.9, value 5.1, each out of 10).

In its favour: Altman Z in the safe zone; Operating margin is expanding. Worth checking: Beneish M-score flags the accounts; Share count keeps rising.

1 of the superinvestors tracked here hold ACAD, including Julian and Felix Baker (5.4% of the portfolio).

Superinvestors holding ACAD

1 of the investors tracked here report a position in their latest 13F filing.

Acadia Pharmaceuticals Inc. (ACAD): questions and answers

What is ACAD's P/E ratio?

Acadia Pharmaceuticals Inc. trades at 8.6× its last twelve months' earnings and 16.8× next year's expected earnings. At its fiscal year-ends over the past 3 years the P/E ranged from 3.1× to 13.5×, with a median of 11.6×.

What is ACAD's PEG ratio?

Acadia Pharmaceuticals Inc.'s PEG ratio is 50.86 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.

What is Acadia Pharmaceuticals Inc.'s market cap?

Acadia Pharmaceuticals Inc. is valued at $3.15B at a share price of $18.20.

Is ACAD overvalued or undervalued?

Against its own history, ACAD is well below its usual price: the price is 36% below the $28.25 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is ACAD above its 200-week moving average?

No. ACAD is 15.5% below its 200-week average of $21.55. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Acadia Pharmaceuticals Inc. growing?

Over the last five fiscal years Acadia Pharmaceuticals Inc.'s revenue grew 19.4% a year; over ten years revenue grew 165.7% a year.

Cite this page

Funkfolio, “Acadia Pharmaceuticals Inc. (ACAD) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/ACAD

Underlying data: Yahoo Finance; company filings with the SEC.